LivaNova to Provide Business Update and Host Webcast and Conference Call on November 12, 2015
LONDON, 2015-10-29 14:00 CET (GLOBE NEWSWIRE) -- LivaNova PLC (NASDAQ:LIVN) (LSE:LIVN) ("LivaNova" or the "Company") today announced that the Company will report sales results for the period ended September 30, 2015, prior to the opening of trading on NASDAQ on November 12, 2015, and will host a business update conference call and webcast that same day at 8:00 AM Central Time (9:00 AM Eastern Time, 2:00 PM GMT).
Sales for LivaNova's three business units will be reported in U.S. dollars for the following periods:
- Cardiac Surgery and Cardiac Rhythm Management – three and nine months ended September 30, 2015
- Neuromodulation – thirteen and thirty-nine weeks ended September 25, 2015
LivaNova's fiscal year ends on December 31 of each year. Cyberonics, Inc. ("Cyberonics"), the predecessor company to LivaNova, previously reported on a 52/53 week fiscal year calendar ending in April of each year. As a result, the historical Neuromodulation business unit sales have been aligned to correspond as closely as possible to the quarter ended September 30, 2015.
LivaNova intends to provide formal financial guidance for fiscal 2016 in February 2016, concurrent with the reporting of financial results for the twelve-month period ended December 31, 2015.
Business Update Webcast and Conference Call Instructions
The conference call will be available to interested parties through a live audio webcast in the Investor Relations section of the LivaNova corporate website at www.livanova.com. To listen to the conference call live by telephone, dial 877-809-8594 (if dialing from within the U.S.) or 440-996-5677 (if dialing from outside the U.S.). The conference ID is 66815767.
Within 24 hours of the webcast, a replay will be available under the "Events & Presentations" section of the Investor Relations portion of the LivaNova website, where it will be archived and accessible for approximately 12 months.
LivaNova, headquartered in London, UK, is a global medical technology company formed by the merger of Sorin S.p.A. ("Sorin"), a leader in the treatment of cardiovascular diseases, and Cyberonics, a medical device company with core expertise in neuromodulation. LivaNova transforms medical innovation into meaningful solutions for the benefit of patients, healthcare professionals, and healthcare systems. The Company employs approximately 4,500 employees worldwide. With a presence in more than 100 countries, LivaNova operates as three business units: Cardiac Rhythm Management, Cardiac Surgery, and Neuromodulation, with operating headquarters in Clamart (France), Mirandola (Italy) and Houston (U.S.), respectively.
LivaNova is listed on NASDAQ and has been admitted to the standard listing segment of the Official List of the UK's Financial Conduct Authority and to trading on the London Stock Exchange (LSE) under the ticker symbol "LIVN".
Safe harbor statement
This press release contains forward-looking statements within the meaning of Section 27A of the United States Securities Act of 1933, as amended and Section 21E of the United States Securities Exchange Act of 1934, as amended. Forward-looking statements are not historical facts but are based on certain assumptions of management and describe the Company's future plans, strategies and expectations. Forward-looking statements can generally be identified by the use of forward-looking terminology, including, but not limited to, "may," "could," "seek," "guidance," "predict," "potential," "likely," "believe," "will," "expect," "anticipate," "estimate," "plan," "intend," "forecast," or variations of these terms and similar expressions, or the negative of these terms or similar expressions. Forward-looking statements contained in this press release are based on information presently available to LivaNova and assumptions that the Company believes to be reasonable, but are inherently uncertain. As a result, our actual results, performance or achievements may differ materially from those expressed or implied by these forward-looking statements, which are not guarantees of future performance and involve known and unknown risks, uncertainties and other factors that are, in some cases, beyond the Company's control. Investors are cautioned that all such statements involve risks and uncertainties, including without limitation, statements concerning developing novel opportunities in heart failure, sleep apnea and percutaneous mitral valve, creating new innovative solutions that benefit patients, healthcare professionals, and healthcare systems, and building significant shareholder value. Important factors that may cause actual results to differ include, but are not limited to: (i) risks that the businesses of Cyberonics and Sorin (together, the "combined companies") will not be integrated successfully or that the combined companies will not realize estimated cost savings, value of certain tax assets, synergies and growth, or that such benefits may take longer to realize than expected; (ii) the inability of LivaNova to meet expectations regarding the timing, completion and accounting of tax treatments; (iii) risks relating to unanticipated costs of integration, including operating costs, customer loss or business disruption being greater than expected; (iv) our organizational and governance structure; (v) reductions in customer spending, a slowdown in customer payments and changes in customer demand for products and services; (vi) unanticipated changes relating to competitive factors in the industries in which LivaNova operates; (vii) the ability to hire and retain key personnel; (viii) the ability to attract new customers and retain existing customers in the manner anticipated; (ix) the reliance on and integration of information technology systems; (x) changes in legislation or governmental regulations affecting LivaNova; (xi) international, national or local economic, social or political conditions that could adversely affect LivaNova, its partners or its customers; (xii) conditions in the credit markets; (xiii) business and other financial risks inherent to the industries in which LivaNova operates; (xiv) risks associated with assumptions made in connection with critical accounting estimates and legal proceedings; (xv) LivaNova's international operations, which are subject to the risks of currency fluctuations and foreign exchange controls; (xvi) and the potential of international unrest, economic downturn or effects of currencies, tax assessments, tax adjustments, anticipated tax rates, raw material costs or availability, benefit or retirement plan costs, or other regulatory compliance costs. The foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and the other risks and uncertainties that affect the parties' businesses, including those described in the "Risk Factors" section of the Registration Statement on Form S-4, Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and other documents filed from time to time with the United States Securities and Exchange Commission by LivaNova. LivaNova does not give any assurance (1) that LivaNova will achieve its expectations, or (2) concerning any result or the timing thereof, in each case, with respect to any regulatory action, administrative proceedings, government investigations, litigation, warning letters, consent decree, cost reductions, business strategies, earnings or revenue trends or future financial results.
All information in this press release is as of the date of its release. The Company does not undertake or assume any obligation to update publicly any of the forward-looking statements in this press release to reflect actual results, new information or future events, changes in assumptions or changes in other factors affecting forward-looking statements, except to the extent required by applicable law. If we update one or more forward-looking statements, no inference should be drawn that we will make additional updates with respect to those or other forward-looking statements. We caution you not to place undue reliance on any forward-looking statements, which are made only as of the date of this press release.
For more information, please visit www.livanova.com,
Chief Financial Officer
Phone: +44 (0)203 786 5281
Fax: +44 (0)203 786 5291
Investor Relations and Media:
Senior Vice President, Finance
Phone: +1 (281) 228-7262
Fax: +1 (281) 218-9332
Om Nasdaq GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York
+1 212 401 8700http://www.nasdaqomx.com
NASDAQ (NASDAQ: NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents.
Følg saker fra Nasdaq GlobeNewswire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Nasdaq GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Nasdaq GlobeNewswire
Brookfield and GLP Establish Partnership to Pursue Rooftop Solar Opportunities in China21.3.2018 09:00 | Pressemelding
All amounts in U.S. dollars unless otherwise stated GLP and Brookfield establish 50:50 joint venture to develop and operate rooftop solar projects on logistics and commercial rooftops in China Partnership intends to become the largest rooftop solar power provider in China Expected to develop and operate capacity of 300 megawatts over the next three years, with a broader 1 gigawatt development pipeline - equivalent to the annual consumption of approximately 750,000 households SHANGHAI, China and NEW YORK, March 21, 2018 (GLOBE NEWSWIRE) -- GLP, the leading global provider of modern logistics and industrial facilities and technology-led solutions, and Brookfield Asset Management (TSX:BAM.A) (NYSE:BAM) (Euronext:BAMA), a leading global alternative asset manager, today announced the formation of a 50:50 joint venture dedicated to building a leading platform for distributed solar energy on logistics and commercial rooftops in China. The joint venture, by affiliates of GLP and Brookfield, in
LCM Partners and Brookfield Asset Management enter into strategic partnership21.3.2018 08:30 | Pressemelding
LONDON and TORONTO, March 21, 2018 (GLOBE NEWSWIRE) -- LCM Partners ("LCM"), a European alternative credit investment manager, announces that it has entered into a strategic partnership with Brookfield Asset Management Inc. (TSX:BAM.A) (NYSE:BAM) (Euronext:BAMA) ("Brookfield"), a leading global alternative asset manager, aimed at jointly growing LCM's leading asset management and credit servicing business globally. Under the terms of the agreement, Brookfield will acquire a 25% strategic interest in Link Financial Group, which comprises both LCM and its sister companies which operate a pan-European loan servicing platform under the Link Financial brand, with an option to acquire another 24.9% interest over time. Link Financial Group was established in the UK in 1998 and has since grown across 10 European offices to become a leading alternative investment manager focussed on credit, and specialised in investing in and servicing consumer, SME, auto, leasing and commercial loans. The firm
VPN.com Puts Netflix CEO Reed Hastings on Notice About Security Risks & VPN Ban21.3.2018 08:00 | Pressemelding
ATLANTA and SAN FRANCISCO, March 21, 2018 (GLOBE NEWSWIRE) -- VPN.com CEO, Michael Gargiulo, is taking the fight to Netflix, Inc. CEO, Reed Hastings, on behalf of 120 million Netflix subscribers worldwide who cannot securely access the service with a Virtual Private Network (VPN). "I wrote this letter because Netflix subscribers are unable to securely connect to the platform they're paying to access," explains Gargiulo. "This comes after Netflix decided to ban VPN connectivity to its platform altogether in 2016, citing copyright concerns from content providers like Sony Corporation, 21st Century Fox, Inc. and NBCUniversal, Inc." Currently, the VPN ban at Netflix forces users to choose between their online security and entertainment. With a large portion of customers connecting via public WiFi-including any of the estimated 500 million hotpots found in coffee shops, airports and hotels worldwide-the liability is omnipresent. "This is a huge problem for Netflix that is coming to a head,"
Boyden Focuses on Expansion in Nordic Region21.3.2018 06:01 | Pressemelding
Premier leadership solutions and talent advisory firm's growth in the Nordics and Northern Europe attracts next generation partners and investment to the region COPENHAGEN, Denmark, March 21, 2018 (GLOBE NEWSWIRE) -- Boyden, a premier global leadership and talent advisory firm with more than 65 offices in over 40 countries, today is announcing transitional changes to its team in Denmark effective 1 July, 2018. Boyden's offices in Sweden, Finland and Norway have experienced significant growth recently, and in support of this growth, Boyden anticipates sharing news on an expansion to the capabilities and expertise in the firm's Denmark office in the near future. "Our clients in the region have come to expect our world-class talent advisory and leadership expertise to help them achieve their growth objectives," said Katarina Brixéus, a Managing Partner of Boyden Sweden. She added, "We will continue to expand our on-the-ground capabilities to meet the aggressive goals of our clients in the
Intesa Sanpaolo, Iberdrola, and Ryanair Among Big Winners on Institutional Investor's 2018 All-Europe Executive Team Rankings21.3.2018 06:00 | Pressemelding
NEW YORK, March 21, 2018 (GLOBE NEWSWIRE) -- Airbus (France), Lonza Group (Switzerland), Nestlé (Switzerland), Allianz (Germany), Subsea 7 (United Kingdom), ASML Holding (Netherlands), Ryanair Holdings (Ireland) - swept their respective sectors, ranking first across the CEO, CFO, and investor relations categories. More than 2,400 buy-side analysts, asset managers, and sell-side researchers at over 800 firms named the best chief executives, top CFOs, investor relations professionals, and investor relations companies across 31 business sectors. Buy-side analysts, money managers and sell-side researchers at securities firms and financial institutions that cover the region identified up to four companies that excel in up to seven investor relations attributes including: Senior executives are accessible IR team is well informed and empowered to speak authoritatively on the company's behalf Timely and appropriate level of financial disclosure Responds quickly and thoroughly to requests Most
Orion Biotechnology Canada Announces Closing of $5 Million Financing20.3.2018 22:03 | Pressemelding
OTTAWA, March 20, 2018 (GLOBE NEWSWIRE) -- Orion Biotechnology Canada Ltd today announced it has completed a US$5 million private placement financing late last year. "We are delighted to have secured the financial resources during this period of rapid expansion," said Mark Groper, President and Chief Executive Officer. "This financing allows Orion, as a private company, to continue development of its expanding pipeline of innovative products, including expansion of our infrastructure and human resources. It also provides external validation of the unique value proposition of the company's pipeline products which include candidates in the areas of Sexual Health, Oncology and Multiple Sclerosis. Orion is a research and development organization committed to developing novel approaches to address serious health issues. A prime example of this is the company's microbicide candidate, OB-001, which is being evaluated as a contraceptive gel which also prevents the transmission of HIV. "This is
I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.Besøk vårt presserom